Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07512466

Evaluation of Endoscopic Management of Sinonasal Tumors In Difficult Anatomical Locations

Research outcome measures:

1. Primary (main):

To Evaluate the Gross Total Resection Rate Using Endoscopic Approach for Lesions Extended To Anatomically Challenging Areas 2. Secondary (subsidiary):

1. Assess postoperative improvement in Quality of Life 2. Quantify intraoperative blood loss and surgical duration 3. Document the incidence of complications (CSF leak, nerve palsy, vascular injury)

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

About this study

Sinonasal tumors are a heterogeneous group of neoplasms arising from the nasal cavity and paranasal sinuses, representing a rare subset of head and neck tumors. Tumors arising from the sinonasal cavity can be subdivided into benign and malignant characters .Sinonasal malignancy are rare, representing <1% of all malignancies and <5% of head and neck cancers.Benign sinonasal tumors are more common than malignant lesions and include inverted papilloma, hemangioma, osteoma, juvenile nasopharyngeal angiofibroma, and various fibrous and glandular neoplasms.(1)The sinonasal cavity includes the epithelial, mesenchymal, salivary gland, cartilaginous and osseous proponents, and as such, it may lead to various original malignancies including the squamous cell carcinoma (most common) and the others (adenocarcinoma, adenoid cystic carcinoma, sarcoma, olfactory neuroblastoma,).(2) Surgical resection is often the first step of the therapeutic strategy in treatment of sinonasal tumors, possibly combined with adjuvant therapies .Tumors at pterygopalatine and infratemporal fossae,sphenoid and maxillary sinus poses challenges to surgeons for their deep location and intimate relationship with highly functional neurovascular and osteo-muscular structures .(3)Tumors in these challenging regions were managed via invasive open surgical resection ,these interventions are frequently morbid, resulting in profound neurological and functional sequelae that adversely impact the patient's clinical outcomes.(4) Endoscopic endonasal surgery become a standard approach in the management of many benign and selected malignant sinonasal tumors .It is as a minimally invasive surgical alternative, facilitating access to difficult locations with preserving the osteo-ligamental and muscular structures with no visible scars, optimal cosmetic outcome, and consequently limited risk of permanent neurological or functional deficits.(5)

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

-Patients with sinonasal and nasopharyngeal tumors

Exclusion criteria

  • Extensive lesions required open approach ex (intraconal extension need orbital exenteration).
  • Absolute contraindications to general anaesthesia.

Treatment and study plan

endoscopic approch

Procedure

mangment of endoscopic approch in sinonasal tumors excision

Primary outcomes

  1. Evaluation of Endoscopic Management of Sinonasal Tumors In Difficult Anatomical Locations

    Time frame: 4 years

    To Evaluate the Gross Total Resection Rate Using Endoscopic Approach for Lesions Extended To Anatomically Challenging Areas

  2. percentage of complete resection post operative

    Time frame: 2 years

    complete resection of tumer by endoscopic approch

Sponsors and collaborators

Lead sponsor

Assiut University

Other

Registry information

Important dates

Study start
2026
Primary completion
2027
Study completion
2028
First posted
Apr 6, 2026
Registry last updated
Apr 6, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.